While the CGT industry is still evolving and developing their own methods, bioprocessing guidelines can be transferred to CGT. CPC connectors are a respected solution provider in bioprocessing can transfer its proven product in the processing of cell and viruses for advanced therapies. Because of that, industry experts expect the single-use technologies (SUTs) with connectors used in biopharmaceutical clinical trials and commercial production to play a large role in the future development and production of CGTs.
SUTs are already used in the development of CGTs today. However, many of those SUTs cannot be transferred from laboratory scale into commercial manufacturing for a variety of reasons, including extractables, leachables, supply chain security, reproducibility, and scalability. These issues will need to be overcome, and solutions developed soon, to meet the pace of CGT development. As CGT manufacturing processes evolve to meet regulatory, economic, and patient safety, some learning will come from bioprocessing, while other learning will have to emerge that is specific to CGTs.
Get a high-level overview about how the use of SUTs in biopharmaceutical manufacturing that can be applied to CGTs, with a special focus on connection technologies.
CELL & GENE THERAPIES: A GUIDE TO SINGLE-USE CONNECTIONS -10 Transferable Lessons From The Bioprocessing Industry